|
|
 |
Ute
Moll, M.D., M.S.
Full Professor,
Department of Pathology
BST L9, R132-136
Stony Brook University
Stony Brook NY 11794-8691
umoll@notes.cc.sunysb.edu
Tel: 631 444 2459
Fax: 631 444 3424
|
|
 |
NOTE:
You will need to Adobe Acrobat Reader installed to
view some of the information on this page. Please visit
www.adobe.com to download the latest version.
|
|
Function
and regulation of the p53 gene family in normal cells
and cancer cells
| p53
is a multi-functional protein that controls a powerful
stress response by integrating signals from many types
of DNA damage, deregulated oncogenes and hypoxia,
leading to p53 activation. Activated p53 elicits apoptosis,
cell cycle arrest or senescence and is involved in
maintaining genomic integrity, thus preventing tumor
formation. Hence, loss of p53 function is a preeminent
finding in human cancers, whether directly through
mutation of p53 itself or through aberrant p53 regulation. |
| p53
induces apoptosis by a dual mode of action. p53 is
a well characterized transcription factor inducing
death-promoting target genes. In addition, we identified
the transcriptionally-independent mitochondrial arm
of p53-mediated apoptosis. Wild-type p53 protein but
not tumor-derived mutants directly interact with and
modulate the anti- and pro-death members of the Bcl-2
family of proteins that control the outer membrane
permeability of mitochondria, thereby releasing apoptotic
activators from the intermembranous space. Understanding
the in vivo regulation and significance of this p53
activity is currently a focus of the lab. We are also
investigating the role of ubiquitination in (dys)regulating
subcellular p53 localization. |
Two
related but structurally complex family members called
p63 and p73 have striking developmental functions.
Another focus of our research is to elucidate their
role in cancer which is complicated by their complex
expression patterns and a lack of clear genetic data.
We use a combination of human tumor material and mouse
models to better understand their action in malignant
transformation.
We found that ablation of the p73 gene reveals a p53-independet
genome stabilization function that suppresses polyploidy
and aneuploidy in primary cells. On the other hand,
we found that human tumors often preferentially upregulate
truncated forms of p73 (so-called DeltaTAp73 isoforms)
that can act as dominant-negative inhibitors of wild-type
p53 and TAp73 and might have prognostic significance
in certain tumors. |

|
|
Selected
Publications (links
will open a new browser window)
|
1)
Talos F, Nemajerova A, Flores E, Petrenko
O, Moll UM. p73 suppresses polyploidy and
aneuploidy in the absence of functional p53.
Mol Cell, in press (Aug 2007).
|
|
2)
Marchenko ND, Wolff S, Erster S, Becker K,
Moll UM. Monoubiquitylation promotes mitochondrial
p53 translocation. EMBO J. 2007 Feb 21;26(4):923-34.
|
|
3)
Becker K, Marchenko ND, Maurice M, Moll UM.
Hyperubiquitylation of wild-type p53 contributes
to cytoplasmic sequestration in neuroblastoma.
Cell Death Differ. 2007 Jul;14(7):1350-60.
|
|
4)
Nemajerova A, Mena P, Fingerle-Rowson G, Moll
UM, Petrenko O. Impaired DNA damage checkpoint
response in MIF-deficient mice. EMBO J. 2007
Feb 21;26(4):987-97.
|
|
5)
Erster S, Palacios G, Rosenquist T, Chang
C, Moll UM. Deregulated expression of DeltaNp73alpha
causes early embryonic lethality. Cell Death
Differ. 2006 Jan;13(1):170-3.
|
|
6)
Palacios G, Moll UM. Mitochondrially targeted
wild-type p53 suppresses growth of mutant
p53 lymphomas in vivo. Oncogene. 2006 Oct
5;25(45):6133-9.
|
|
7)
Talos F, Petrenko O, Mena P, Moll UM. Mitochondrially
targeted p53 has tumor suppressor activities
in vivo. Cancer Res. 2005 Nov 1;65(21):9971-81.
|
|
8)
Petrenko O, Moll UM. Macrophage migration
inhibitory factor MIF interferes with the
Rb-E2F pathway. Mol Cell. 2005 Jan 21;17(2):225-36.
|
|
9)
Concin, N., Becker, K., Slade, N., Erster,
S., Mueller-Holzner, E., Ulmer, H., Daxenbichler,
G., Zeimet, A., Zeillinger, R., Marth, C.
and Moll, U.M. (2004) Transdominant DeltaTAp73
isoforms are frequently up-regulated in ovarian
cancer. Evidence for their role as epigenetic
p53 inhibitors in vivo. Cancer Res, 64, 2449-2460.
|
|
10)
Mihara M, Erster S, Zaika A, Petrenko O.,
Chittenden T.,Pancoska P., Moll UM. p53 has
a direct apoptogenic role at the mitochondria.
Mol Cell. 2003 Mar;11(3):577-90.
|
|
11)
Petrenko, O., Zaika, A., Moll, U.M. (2003)
deltaNp73 facilitates cell immortalization
and cooperates with oncogenic Ras in cellular
transformation in vivo. Mol Cell Biol, 23,
5540-5555.
|
|
12)
Zaika, A.I., Slade, N., Erster, S.H., Sansome,
C., Joseph, T.W., Pearl, M., Chalas, E. and
Moll, U.M. (2002) DeltaNp73, a dominant-negative
inhibitor of wild-type p53 and TAp73, is up-regulated
in human tumors. J Exp Med, 196, 765-780.
|
|
|
|
|